1 month Why AnaptysBio Was Such a Healthy Stock This Week The Motley Fool
The company’s immediate future looks promising, as it has a drug that should get a clinical readout within months and a deep-pocketed pharmaceutical peer as an investor.
The company’s immediate future looks promising, as it has a drug that should get a clinical readout within months and a deep-pocketed pharmaceutical peer as an investor.